Clarus Therapeutics (CRXTQ) Stock Price, News & Analysis

Company Overview

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company focused on developing and commercializing treatments for men’s health conditions, particularly testosterone deficiency and hypogonadism. The company’s activities have centered on prescription therapies intended to address inadequate levels of endogenous testosterone in adult men.

Clarus’s primary product is JATENZO, an oral testosterone undecanoate softgel capsule. The U.S. Food and Drug Administration approved JATENZO in 2019 for testosterone replacement therapy in adult males with hypogonadism associated with certain medical conditions. The product was developed as an oral alternative to other testosterone-delivery methods, including injections, topical gels and patches, and has been marketed in the United States.

Clarus Therapeutics was established in the United States and has focused primarily on the U.S. men’s health market. The company subsequently entered financial restructuring proceedings, and its securities have traded under the OTC ticker CRXTQ. Information regarding its current operations, commercial activities and leadership is limited.

Key Stats

• Today's Range: $0.0010 to $0.0010
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $3.94
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/18/2021
• Today: 10/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Finance
• Industry: Capital Markets
• Sub-Industry: Asset Management & Custody Banks
• Current Symbol: OTCMKTS:CRXTQ
• CIK: 1817944
• Web: www.clarustherapeutics.com
• Phone: 847-562-4300
• Fax: N/A
• Employees: 2
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A